Identification and Structure-Activity Studies of 1,3-Dibenzyl-2-aryl imidazolidines as Novel Hsp90 Inhibitors

Article abstract of DOI:10.3390/molecules24112105

Hsp90 (Heat shock protein 90) is involved in various processes in cancer occurrence and development, and therefore represents a promising drug target for cancer therapy. In this work, a virtual screening strategy was employed, leading to the identificatio

Full text of DOI:10.3390/molecules24112105

molecules
Communication
Identification and Structure-Activity Studies of
1,3-Dibenzyl-2-aryl imidazolidines as Novel
Hsp90 Inhibitors
Yajun Liu *, Xiaoxia Liu, Lihong Li, Rui Dai, Meiyun Shi, Hongyu Xue *, Yong Liu and
Hecheng Wang
School of Life Science and Medicine, Dalian University of Technology, Dagong Road No. 2, Panjin 124221, China;
lxx890720@mail.dlut.edu.cn (X.L.); 1408064107@mail.dlut.edu.cn (L.L.); dairui666@mail.dlut.edu.cn (R.D.);
shimy@dlut.edu.cn (M.S.); yliu@dlut.edu.cn (Y.L.); wanghc@dlut.edu.cn (H.W.)
* Correspondence: yjliu85@dlut.edu.cn (Y.L.); hongyuxue@dlut.edu.cn (H.X.); Tel.: +86-427-263-1427 (Y.L.)
ꢀꢁꢂꢀꢃꢄꢅꢆꢇ
Academic Editor: Liangren Zhang
Received: 28 February 2019; Accepted: 31 May 2019; Published: 3 June 2019
ꢀꢁꢂꢃꢄꢅꢆ
Abstract: Hsp90 (Heat shock protein 90) is involved in various processes in cancer occurrence and
development, and therefore represents a promising drug target for cancer therapy. In this work, a
virtual screening strategy was employed, leading to the identification of a series of compounds bearing
a scaffold of 1,3-dibenzyl-2-aryl imidazolidine as novel Hsp90 inhibitors. Compound 4a showed the
highest binding affinity to Hsp90
and the strongest anti-proliferative activity against human breast adenocarcinoma cell line (MCF-7)
and human lung epithelial cell line (A549) with IC50 values of 21.58 M and 31.22 M, respectively.
α (IC50 = 12 nM) in fluorescence polarization (FP) competition assay
µ
µ
Western blotting assays revealed that these novel Hsp90 inhibitors significantly down-regulated the
expression level of Her2, a client protein of Hsp90, resulting in the cytotoxicity of these novel Hsp90
inhibitors. The molecular docking study showed that these novel Hsp90 inhibitors bound to the
adenosine triphosphate (ATP) binding site at the N-terminus of Hsp90. Furthermore, structure–activity
relationship studies indicated that the N-benzyl group is important for the anti-cancer activity of
1,3-dibenzyl-2-aryl imidazolidines.
Keywords: Hsp90; imidazolidine; anti-cancer; molecule docking; virtual screening
1. Introduction
Hsp90 is a molecular chaperone with the molecular weight of 90 kD in the family of heat
shock proteins. It plays an important role in maintaining conformations and biological functions
of various oncoproteins, which are indispensable for the occurrence and progression of various
cancers, including melanoma, breast cancer, gastrointestinal stromal tumors, and lung cancer [
The expression level of Hsp90 in cancer cells is much higher than it in normal cells, which makes it an
attractive drug target for the therapy of cancers [ 11]. Inhibition of Hsp90 in cancer cells causes the
degradation of client oncoproteins, and thus Hsp90 inhibitor is considered as a prominent strategy for
the therapy of cancers [12 14]. In addition to cancer, Hsp90 has been found as potential drug target
1–6].
7
–
–
for neurodegenerative diseases (e.g., Alzheimer’s disease [15], Parkinson disease [16], Huntington
disease [17]), viral disease, [18] fungal disease [19], and parasitic disease) [20].
Binding and hydrolysis of ATP at the N-terminus of Hsp90 provides energy for client protein
folding, and inhibiting this process will result in ubiquitinylation of the substrate and induce degradation
of client protein via the proteasome. Generally, Hsp90 inhibitors are designed to competitively target
the ATP binding site at the N-terminal of Hsp90 and inhibit the ATPase activity of Hsp90 [21
–24].
The first generation of Hsp90 inhibitors were derived from natural products [25]. Geldanamycin is the
Molecules 2019, 24, 2105; doi:10.3390/molecules24112105
www.mdpi.com/journal/molecules

Molecules 2019, 24, 2105
2 of 11
first identified Hsp90 inhibitor, however the dose and schedule-dependent toxicity limits its further
development [26]. Modification of geldanamycin led to the identification of 17-AAG, which was the
first Hsp90 inhibitor entered into clinical trials in 1999 [27]. Although it has low toxicity and better
water solubility in comparison to geldanamycin, it was recently retired from clinical trials. Radicicol is
the second natural Hsp90 inhibitor, but it is inactive in human tumor xenografts in mouse models due
to its chemical instability [28]. The following studies developed many small molecule inhibitors with
scaffolds of various kinds as the second generation of Hsp90 inhibitors (Figure 1). Inspired by radicicol,
many resorcinol-based inhibitors, including NVP-AUY922, [29
,
30] STA-9090, [31] KW-2478 [32
,33],
and SNX-5422 [34], have been designed. In addition, purine- [35
,36] and benzamide-based [37] small
molecule Hsp90 inhibitors have also been developed for clinical trials.
Figure 1. Representative Hsp90 inhibitors in clinical trials.
There are eighteen Hsp90 inhibitors that have been entered into clinical trials. Unfortunately, no
Hsp90 inhibitors have been approved by the Food and Drug Administration (FDA). Thus, there is still
a need to further develop and amplify inhibitor scaffolds for more novel Hsp90 inhibitors. Herein, we
described a virtual screening-based method for identifying novel Hsp90 inhibitors. A virtual library
containing 300,000 small molecules was screened using Discovery Studio, and 1,3-dibenzyl-2-aryl
imidazolidines were identified as novel Hsp90 inhibitors in biochemical and cellular assays.
2. Results and Discussion
2.1. Structure Based Virtual Screening
In order to obtain Hsp90 inhibitors with novel central scaffolds, a small molecule library containing
300,000 molecules was downloaded from Specs and virtually screened. As shown in Figure 2, this
small molecule library was initially screened by Lipinski’s Five Rules to exclude molecules with
possibly poor drug-like properties. In total, 84,102 molecules entered the next round for molecule
docking. The ATP binding site at the N-terminal of Hsp90 (protein data bank code: 4CE1) was chosen
as the active site. Molecule docking was performed by 2 steps: (1) rigid docking module LibDock
provided fast screening and the molecules were ranked by LibDock score; (2) the top 800 molecules
were further docked with Hsp90 using a semi-flexible docking method CDOCKER and ranked by
“CDOCKER_ENERGY”. Finally, the top 21 molecules were selected for further biological studies.

Molecules 2019, 24, 2105
3 of 11
Figure 2. Workflow of the virtual screening protocol for Hsp90 inhibitor development.
2.2. Biological Evaluation of Molecules Identified from Virtual Screening
The 21 compounds were divided into 5 groups by their different characteristic scaffolds, including
triazoles (1a 1d), benzimidazoles (2a 2c), aryl sulfonyls (3a 3e), imidazolidines (4a 4b), and others
5a 5g) (Figure 3). The anti-proliferative activity against MCF-7 cells of these 21 compounds were
evaluated using MTT assay. The IC50 values ranged from 21.58 M to 322 M. Compounds 4a
–
–
–
,
(
–
µ
µ
and 4b, each bearing an imidazolidine scaffold, attracted our attention because of their relatively
strong anti-cancer activity and novel chemical structure. Compound 4a exhibited the strongest
anti-proliferative activity towards MCF-7 cells, with an IC50 value of 21.58 µM. To the best of our
knowledge, 2-aryl-imidazolidines have never been reported as either anti-cancer agents or Hsp90
inhibitors. Thus, 4a was taken as a hit compound to develop more novel Hsp90 inhibitors with 2-aryl
imidazolidine as the central scaffold.
Figure 3. Chemical structures and anti-proliferative activity (IC50 = the mean
MCF-7 cells of the top 21 molecules identified from the virtual screening (positive control: 17-AAG,
±
SD µM, n = 3) against
IC50 = 7.18 ± 0.13 µM).
2.3. Molecule Docking Analysis of Hsp90-4a Complex
To gain a better understanding of the binding mode of 4a and Hsp90, the molecular docking
result of 4a with the N-terminal of the ATP binding pocket of the yeast Hsp90 was studied. As shown

Molecules 2019, 24, 2105
4 of 11
in Figure 4, 4a occupied the ATP binding cavity at the N-terminal of Hsp90. The nitro group on
the thiophene ring formed 2 hydrogen bonds with PHE124 and ASN37, respectively. Benzyl groups
formed hydrophobic bonds with amino acid residues of Hsp90. This result indicated that a hydrogen
bond acceptor at the 2-position of imidazolidine and a hydrophobic fragment at the nitrogen atoms are
favorable for this kind of molecule to bind Hsp90.
Figure 4. Molecular docking analysis of the 4a-yeast Hsp90 complex. Predicted binding mode of 4a
and Hsp90. Hydrogen bonds are indicated by green dashed lines. The Pi-alkyl interaction is shown by
a pink dashed line.
2.4. Structure-Activity Relationship (SAR) Studies
In order to get more Hsp90 inhibitors with potent anti-cancer activities, a series of 1,3-dibenzyl-2-
aryl imidazolidines with different aryl groups (4c–4r) were designed based on the predicted binding
mode of 4a and Hsp90. As Table 1 showed, these kinds of compounds were readily synthesized through
a condensation of N,N0-dibenzyl ethylenediamine with the corresponding (hetero)aryl aldehydes.
Pure products were easily obtained by filtration and washing with cold ethanol. The nuclear magnetic
resonance (NMR) spectra of all synthesized compounds can be found in the Supplementary Materials.
Anti-cancer activities of the synthesized compounds were evaluated using human breast cancer MCF-7
cell line and adenocarcinomic human alveolar basal epithelial A549 cell line. 17-AAG was used as the
positive control.
As shown in the molecule docking study, the nitro group played an important role in the interaction
of 4a and Hsp90, and we studied the effect of the nitro group on antitumor activity. Removal of
the nitro group (4c) or replacing nitro with other functional groups (4d–4f) led to a decrease in the
cytotoxicity. When the thiophene ring in 4a was replaced by the phenyl ring, the position effect of
the nitro group was observed as ortho-nitro-substituted phenyl (4g), which gave better activity than
the para-substituted one (4h). Considering that nitrothiophene is a hydrogen bond acceptor, various
analogues (4i
synthesized analogues, 4i bearing a 2-fuloro-5-chloro ring exhibited the strongest anti-proliferative
activity against MCF-7 cells with IC50 of 27.86 M, and 4j with a 2-chloro-thiazol-5-yl group inhibited
–4r) bearing a broad range of hydrogen bond acceptors were synthesized. Among these
µ
the proliferation of A549 cells with IC50 of 35.3 µM.
The effect of different substituents on two nitrogen atoms on the biological activity was
subsequently studied (Table 2). The benzyl group is more favorable as the anticancer activity
significantly decreased when the benzyl group of a larger size was replaced by smaller groups,
including phenyl (6a
–6d), ethyl (7a, 7b), and methyl groups (8a). This may be because small groups
cannot form stable hydrophobic bonds with amino acid residues in the ATP binding site of Hsp90.

Molecules 2019, 24, 2105
5 of 11
Table 1. Structure of 4a
–
4r and their IC50 values (µM) on MCF-7 and A549 cell lines, 48-h post treatment.
a
IC50 (µM)
MCF-7
Entry
Product
Ar
A549
1
2
4a
4b
21.58 ± 0.57
50.62 ± 0.26
31.22 ± 0.31
88.58 ± 0.08
3
4
4c
80.04 ± 0.63
68.35 ± 0.44
78.18 ± 0.15
56.30 ± 1.27
4d
5
6
4e
4f
119.30 ± 0.42
219.40 ± 0.57
112.80 ± 1.41
135.80 ± 1.41
7
8
4g
4h
40.91 ± 0.05
117.70 ± 0.01
40.64 ± 0.51
55.60 ± 0.49
9
4i
4j
27.86 ± 0.01
33.12 ± 0.23
77.01 ± 0.01
31.48 ± 0.60
59.27 ± 0.83
35.30 ± 0.14
498.80 ± 0.25
64.66 ± 0.48
10
11
12
4k
4l
13
4m
76.42 ± 0.31
70.42 ± 0.10
14
15
16
17
4n
4o
4p
4q
40.36 ± 0.51
53.12 ± 0.77
45.25 ± 0.63
46.97 ± 0.04
52.11 ± 0.50
56.92 ± 1.27
72.87 ± 0.66
71.36 ± 0.88
18
19
4r
51.37 ± 0.54
7.18 ± 0.13
80.78 ± 1.00
3.54 ± 0.08
17-AAG
-
a
The IC50 values are shown as the mean ± SD (µM) from three separate experiments.

Molecules 2019, 24, 2105
6 of 11
Table 2. Effect of substituents of nitrogen atoms on the anti-proliferative activity against MCF-7 cells
and A549 cells, respectively.
a
IC50 (µM)
MCF-7
Entry
R
Ar
Product
6a
A549
1
2
Ph
Ph
40.77 ± 0.39
161.60 ± 0.57
123.40 ± 0.85
172.00 ± 1.41
6b
6c
3
4
5
6
7
Ph
Ph
Et
43.67 ± 1.03
323.00 ± 2.28
>500
46.14 ± 0.20
248.60 ± 0.57
250.10 ± 1.27
164.00 ± 1.41
148.70 ± 1.56
6d
7a
7b
8a
Et
158.90 ± 0.14
250.10 ± 0.27
Me
a
The IC50 values are shown as the mean ± SD (µM) from three separate experiments.
2.5. Binding Affinity Assay
In order to invalidate the inhibitory effect of these imidazolidines on Hsp90, 8 compounds were
selected for Fluorescence polarization (FP) competitive binding assay. As shown in Table 3, 6 of the
8 compounds in this series exhibited FP IC50 values at the nanomolar level, indicating high binding
affinity to Hsp90α. Consistent with the anti-proliferative activity, 4a showed the strongest binding
affinity to human Hsp90α with IC50 value of 12 nM in the FP assay, compared with other analogues.
Table 3. FP activities on Hsp90 of selected 2-aryl imidazolidines.
Compounds
FP IC50 (µM) a
17-AAG
0.017 ± 0.003
0.012 ± 0.010
0.612 ± 0.014
0.672 ± 0.010
0.610 ± 0.014
0.310 ± 0.014
0.102 ± 0.010
1.930 ± 0.013
4a
4b
4d
4i
4j
4n
6c
a
The IC50 values are shown as the mean ± SD (µM) from three separate experiments.
2.6. Western Blotting Assay
In order to get more evidence of the Hsp90 inhibition ability of 1,3-dibenzyl-2-aryl imidazolidines,
the effects of 4a and 4b on the expression level of Her2, an important client protein of Hsp90, was
studied. The expression levels of Her2, Hsp70, and Hsp90 were measured by western blotting, using
17-AAG as the positive control. MCF-7 cells were incubated with compound 4a and 4b at IC50
concentrations for 24 h (Figure 5a). Compound 4a and 4b significantly down-regulated the expression
level of Her2. It is interesting that 4a at IC50 concentration down-regulated the expression level of
Her2 to 48%, indicating that the anti-proliferative activity of 4a against MCF-7 cells was a consequence
of Hsp90 inhibition. On the other side, 4a and 4b significantly induced the expression of Hsp70

Molecules 2019, 24, 2105
7 of 11
and slightly increased the expression of Hsp90. In another experiment, after exposure for 24 h to
4j at different concentrations, the expression levels of Her2, Hsp70, and Hsp90 in MCF-7 cells were
regulated by 4j in a concentration-dependent manner (Figure 5b). Taken together, 1,3-dibenzyl-2-aryl
imidazolidines exhibited their anticancer activity through modulating the Hsp90 function.
Figure 5. Western blotting assay. (
and Hsp90 in the MCF-7 cell line. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used in
a loading control. ( ) Effects of compound 4j (0, 5, 10, 20, and 40 M) on the expression of Her2, Hsp70,
a) Effects of 17-AAG, 4a, and 4b on the expression of Her2, Hsp70,
b
µ
and Hsp90 in the MCF-7 cell line.
3. Materials and Methods
3.1. Virtual Screening
The small molecule library for virtual screening was downloaded from Specs (www.specs.net).
Virtual screening was carried out using Discovery Studio 2016 (Accelrys®, San Diego, CA, USA). The
small library was first filtered by Lipinski’s rule of five (“Molecule Weight” was set to “200–500”,
“H_Acceptors” to “less than 10”, “H_Donors” to “less than 5”, “ClogP” to “less than 5”). The resulting
molecules were further screened by molecular docking. The cocrystal structure of radicicol bound
to yeast Hsp90 (PDB ID: 4CE1; 2.01 Å resolution) was downloaded from the Protein Data Bank
(www.rcsb.org). Radicicol was removed from the complex and the resulting protein was prepared
using “prepare protein” to remove water molecules and add hydrogens. The binding site of radicicol
in Hsp90 was selected as the active site (radius: 9 Å). The small molecule library was imported and
docked with Hsp90 using CHARMm (Chemistry at HARvard Macromolecular Mechanics) force field.
The molecule docking was first carried out using “LibDock” and ranked by “LibDockScore”. The top
1% of ranked molecules were further docked into the same active site of Hsp90 using “CDOCKER”
and ranked by “-CDOCKER_ENERGY”. The predicted binding mode of molecule 4a was selected
according to the lowest binding free energy.
3.2. Evaluation of Anti-proliferative Activity In Vitro
The anti-proliferative activity of compounds was determined by MTT (3-[4,5-dimethylthiazole-
2-yl]-2,5-diphenyltetrazolium bromide) assay on MCF-7 and A549 cell lines, respectively. Cells
were purchased from the Institute of Basic Medical Science, Chinese Academy of Medical Science

Molecules 2019, 24, 2105
8 of 11
(Beijing, China). Cells were maintained in RPMI-1640 with 10% fetal bovine serum (FBS) and 1%
Penicillin-Streptomycin Solution (PS) and cultured at 37 ◦C in a humidified atmosphere containing 5%
CO2. Compounds to be evaluated were dissolved in DMSO (dimethyl sulfoxide), diluted in RPMI-1640,
and stored at
(200 L) and incubated overnight. Culture medium was replaced with fresh RPMI (Roswell Park
Memorial Institute)-1640 containing compounds in different concentrations (100 M–50 M–25 M–
12.5 M–6.25 M–3.125 M). Then, cells were incubated in a 5% CO2 incubator for 48 h. The 20
MTT solution (5 mg/mL) was added to each well and incubated at 37 ◦C. After 4 h, the medium was
removed and formazan crystals were dissolved in 100 L DMSO. Absorbance was measured at a
−
20 ◦C before use. Cells were seeded in 96-well plates at a density of 5000 cells/well
µ
µ
µ
µ
µ
µ
µ
µL
µ
wavelength of 490 nm using Synergy H1 (BioTek Instruments, Inc., Winooski, VT, USA). IC50 values
were calculated by GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA).
3.3. Fluorescence Polarization (FP) Enzymatic Assay
In vitro inhibitory activity of compounds on Hsp90 was carried out in 96-well plates by FP assay
using Hsp90
to the manufacturer’s instructions. In brief, the Hsp90 assay buffer (15
(DTT) (5 L), 2 mg/mL BSA (5 L), and H2O (40 L) were added to the plate. To each well, 100 nM
fluorescein isothiocyanate (FITC)-labeled geldanamycin (5 L) and diluted compounds in different
concentrations (0.5, 5, 50, 500 M, 10 L) were added in an orderly manner. The reactions were initiated
by adding 20 L of Hsp90 (17 ng/ L). After 2.5 h incubation with slow shaking at room temperature,
the fluorescence intensity was measured at ex 485 nm and em 530 nm using Synergy H1 (BioTek
α
N-Terminal Domain Assay Kit (BPS Bioscience, Catalog #50293, CA, USA) according
µL), 40 mM dithiothreitol
µ
µ
µ
µ
µ
µ
µ
α
µ
λ
λ
Instruments, Inc.). The data were analyzed using GraphPad Prism 5 (GraphPad Software, Inc.).
3.4. Western Immune Blotting Assays
Primary antibodies against Hsp70, Hsp90, Her2, and GAPDH were bought from Abcam
(Cambridge, MA, USA). HRP (horseradish peroxidase) labeled anti-rabbit immunoglobulin G (H
+ L) secondary antibody was purchased from Abbkine (Redlands, CA, USA). MCF-7 cells were
cultured as described above to a density of 106 cells per dish. The cells were treated with different
◦
concentrations of drugs or 17-AAG in RPMI-1640 for 24 h at 37 C. Cells were washed with cold
phosphate buffered saline (PBS, pH = 7.4) three times and lysed in radio immunoprecipitation assay
(RIPA) lysate (containing 1% phenylmethanesulfonyl fluoride (PMSF)) on ice for 45 min. The lysates
were collected and clarified at 12,000
Protein concentration was determined by the bicinchoninic acid (BCA) protein assay kit. The protein
sample (20 g) was electrophoresed using 8% SDS-PAGE (sodium dodecyl sulfate- polyacrylamide gel
×
g for 20 min at 4 ◦C using high speed refrigerated centrifuge.
µ
electrophoresis), transferred to poly(vinylidene fluoride) (PVDF) membranes, and then blocked for 1 h
in 5% skim milk in TBST (20 mM Tris-HCl pH 7.4, 100 mM NaCl, and 0.1% Tween 20). The membranes
were immunoblotted with primary antibodies for 2 h at room temperature. After incubation with an
HRP anti-rabbit IgG (H + L) (1:100,000) as a secondary antibody, the bands were detected using the
ECLTM Prime Western Blotting Detection System (ProteinSimple, San Jose, CA, USA). The density of
proteins was determined using the AlphaView SA (Alpha Innotech Corp., version 3.4.0.0, San Leandro,
CA, USA).
3.5. Chemistry
3.5.1. General Information
All chemicals were purchased as reagent grade and used without further purification. The 1H
and 13C-NMR spectra were carried out on an AVANCE III HD 500 MHz nuclear magnetic resonance
spectrometer (Bruker, Billerica, MA, USA). The high resolution mass spectrometry (HRMS) was
carried out on a Q Exactive mass spectrometer (Thermo Fisher, Waltham, MA, USA) with electrospray
ionization ESI) as the ionization source.

Molecules 2019, 24, 2105
9 of 11
3.5.2. General Procedure for the Preparation of 1,3-Dibenzyl-2-aryl Imidazolidine 4c–4r
The corresponding aldehydes (1.0 mmol) were added to a solution of N,N0-dibenzyl
ethylenediamine (480 mg, 2.0 mmol) in aqueous ethanol (50%, 3 mL). The reaction mixture was
stirred at room temperature until the complete consumption of aldehydes, as determined by thin layer
chromatography (TLC). The mixture was filtered and the filter cake was washed with a small amount
of water and cold ethanol to afford the pure product.
3.5.3. General Procedure for the Preparation of N,N0-Diphenyl-2-aryl Imidazolidine 6a–6d
The corresponding aldehyde (1.0 mmol) was added to a solution of N,N0-diphenyl ethylenediamine
(424 mg, 2.0 mmol) in aqueous ethanol (50%, 3 mL). The reaction mixture was stirred at room temperature
until the complete consumption of aldehydes, as determined by TLC. The mixture was filtered and the
filter cake was washed with a small amount of water and cold ethanol to afford the pure product.
3.5.4. General Procedure for Preparation of 1,3-Diethyl-2-aryl Imidazolidine 7a,7b
The corresponding aldehyde (1.0 mmol) was added to a solution of N,N0-diethyl-ethylenediamine
(430 µ
L, 3.0 mmol) in aqueous ethanol (50 %, 3 mL). The reaction mixture was stirred at 80 ◦C until
the complete consumption of aldehydes, as determined by TLC. After cooling to room temperature,
the reaction mixture was extracted with ethyl acetate and water. The organic layer was dried over
anhydrous MgSO4 and concentrated in vacuum to afford the corresponding product.
3.5.5. General Procedure for Preparation of N,N0-Dimethyl-2-aryl Imidazolidine 8a
The corresponding aldehyde (1.0 mmol) was added to a solution of N,N0-dimethyl-ethylenedi◦amine
(323 µL, 3.0 mmol) in aqueous ethanol (50%, 3 mL). The reaction mixture was stirred at 80 C for
3 h until the complete consumption of aldehydes, as determined by TLC. After cooling to room
temperature, the reaction mixture was extracted with ethyl acetate and water. The organic layer was
dried over anhydrous MgSO4 and concentrated in a vacuum to afford the corresponding product.
4. Conclusions
In this work, a series of novel Hsp90 inhibitors with a scaffold of 1,3-dibenzyl-2-aryl imidazolidine
were identified using a strategy of virtual screening. These novel Hsp90 inhibitors showed evident
anti-proliferative activity against MCF-7 and A549 cell lines. The compounds of this kind exhibited
strong binding affinity to human Hsp90α in FP assay. Western immune blotting assays revealed that
these compounds displayed the characteristic molecular biomarker of Hsp90 inhibition, such as the
downregulation of Her2 and upregulation of Hsp70 and Hsp90 in MCF-7 cell lines. Typically, 4a
at IC50 concentration down-regulated the expression level of Her2 to 48%, providing an additional
experimental evidence that 4a exhibited its anti-proliferative activity by inhibiting the Hsp90 chaperone.
Molecule docking studies revealed the aryl moiety is responsible for the formation of hydrogen bonds
and benzyl moieties participate in the hydrophobic bond formation with amino acid residues in the
ATP binding pocket at the N-terminal of Hsp90.
In conclusion, our work provided 4a as a novel and promising lead for further development of
Hsp90 inhibitors as anticancer drugs. It should be noted that these imidazolidines, such as 4a, exhibited
strong Hsp90 inhibition ability in FP assay, but the IC50 values of 4a in cellular antiproliferation assay
are at the micromole level. This discrepancy may be attributed to the poor cellular uptake efficacy
or instability of the test compound. Our future work will focus on the in vitro pharmacokinetic
evaluation of 4a, and a structure-activity study on the imidazolidine ring by replacing it with a range
of bioisosteres.

Molecules 2019, 24, 2105
10 of 11
5. Patents
Part of the work reported in this paper has been applied for a Chinese patent (Y. Liu, X. Liu, M.
Shi, H. Wang, CN108822089A, 2018).
Supplementary Materials: The following are available online, Analytical data and NMR spectra of
prepared compounds.
Author Contributions: Y.L. (Yajun Liu) set the topic, designed the study, interpreted the results, and wrote
the paper. X.L. performed the virtual screening, prepared compounds, and carried out the FP assay and
western blotting assay. R.D. synthesized compounds. M.S. determined chemical structures. H.X. and Y.L. (Yong
Liu) designed the study. L.L. tested the biological activity against MCF-7. H.W. tested the biological activity
against A549.
Funding: This research was funded by the National Natural Science Foundation of China (Grant No. 81703607),
Natural Science Foundation of Liaoning Province of China (Grant No. 20170540148), and Fundamental Research
Funds for the Central Universities (Grant No. DUT17LK23).
Conflicts of Interest: The authors declare no conflict of interest.
References
1.
2.
3.
4.
Sherman, M.; Multhoff, G. Heat shock proteins in cancer. Ann. N. Y. Acad. Sci. 2007, 1113, 192–201. [CrossRef]
[PubMed]
Whitesell, L.; Lindquist, S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5, 761. [CrossRef]
[PubMed]
Wandinger, S.; Richter, K.; Buchner, J. The Hsp90 chaperone machinery. J. Biol. Chem. 2008, 283, 18473–18477.
[CrossRef] [PubMed]
Pearl, L.; Prodromou, C. Structure and mechanism of the Hsp90 molecular chaperone machinery.
Annu. Rev. Biochem. 2006, 75, 271–294. [CrossRef] [PubMed]
5.
6.
Graner, M. HSP90 and immune Modulation in cancer. Adv. Cancer Res. 2016, 129, 191–224. [PubMed]
Wong, D.; Jay, D. Emerging roles of extracellular hsp90 in cancer. Adv. Cancer Res. 2016, 129, 141–163.
[PubMed]
7.
8.
9.
Miyata, Y.; Nakamoto, H.; Neckers, L. The therapeutic target Hsp90 and cancer hallmarks. Curr. Pharm. Des.
2013, 19, 347–365. [CrossRef] [PubMed]
Maloney, A.; Workman, P. HSP90 as a new therapeutic target for cancer therapy: The story unfolds.
Expert Opin. Biol. Ther. 2002, 2, 3–24. [CrossRef]
Moser, C.; Lang, S.; Stoeltzing, O. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of
gastrointestinal cancer. Anticancer Res. 2009, 29, 2031–2042.
10. Beliakoff, J.; Whitesell, L. Hsp90: An emerging target for breast cancer therapy. Anticancer Drugs 2004, 15,
651–662. [CrossRef]
11. Mahalingam, D.; Swords, R.; Carew, J.; Nawrocki, S.; Bhalla, K.; Giles, F. Targeting HSP90 for cancer therapy.
Br. J. Cancer 2009, 100, 1523–1529. [CrossRef] [PubMed]
12. Özgür, A.; Tutar, Y. Heat shock protein 90 inhibition in cancer drug discovery: From chemistry to futural
clinical applications. Anticancer Agents Med. Chem. 2016, 16, 280–290. [CrossRef] [PubMed]
13. Gomez-Monterrey, I.; Sala, M.; Musella, S.; Campiglia, P. Heat shock protein 90 inhibitors as therapeutic
agents. Recent Pat. Anticancer Drug Discov. 2012, 7, 313–336. [CrossRef] [PubMed]
14. Bhat, R.; Tummalapalli, R.; Rotella, D. Progress in the discovery and development of heat shock protein 90
(Hsp90) inhibitors: Miniperspective. J. Med. Chem. 2014, 57, 8718–8728. [CrossRef] [PubMed]
15. Claudia, C.; Andrea, P.; Celeste, C.; Paola, M.; Antonella, M.; Silvestre, B. Heat shock proteins in alzheimer’s
disease: Role and targeting. Int. J. Mol. Sci. 2018, 19, 10.
16. Lackie, R.; Maciejewski, A.; Ostapchenko, V.; Marques-Lopes, J. The Hsp70/Hsp90 Chaperone machinery in
neurodegenerative diseases. Front Neurosci. 2017, 11, 254. [CrossRef] [PubMed]
17. Ernst, J.; Neubert, T.; Liu, M.; Sperry, S.; Zuccola, H. Identification of novel HSP90α/β isoform selective
inhibitors using structure-based drug design demonstration of potential utility in treating CNS disorders
such as Huntington’s disease. J. Med. Chem. 2014, 57, 3382–3400. [CrossRef] [PubMed]
18. Wang, Y.; Jin, F.; Wang, R.; Li, F.; Wu, Y.; Kitazato, K.; Wang, Y. HSP90: A promising broad-spectrum antiviral
drug target. Arch. Virol. 2017, 162, 3269–3282. [CrossRef] [PubMed]

Molecules 2019, 24, 2105
11 of 11
19. Cowen, L.; Singh, S.; Kohler, J.; Collins, C.; Zaas, A. Harnessing Hsp90 function as a powerful, broadly
effective therapeutic strategy for fungal infectious disease. Proc. Natl. Acad. Sci. USA 2009, 106, 2818–2823.
[CrossRef]
20. Devaney, E.; Gillan, V. Hsp90 Inhibitors in parasitic nematodes: Prospects and challenges. Curr. Top
Med. Chem. 2016, 16, 2805–2811. [CrossRef]
21. Wang, H.; Lu, M.; Yao, M.; Zhu, W. Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase
II clinical trials. Mol. Clin. Oncol. 2016, 5, 326–334. [CrossRef] [PubMed]
22. Yuno, A.; Lee, M.; Lee, S.; Tomita, Y.; Rekhtman, D.; Moore, B.; Trepel, J. Clinical evaluation and biomarker
profiling of hsp90 inhibitors. Methods Mol. Boil. 2018, 1709, 423–441.
23. Jhaveri, K.; Taldone, T.; Modi, S.; Chiosis, G. Advances in the clinical development of heat shock protein 90
(Hsp90) inhibitors in cancers. BBA Mol. Cell Res. 2012, 1823, 742–755. [CrossRef] [PubMed]
24. Petrikaite, V.; Matulis, D. Binding of natural and synthetic inhibitors to heat shock protein 90 and their
clinical applications. Medicina (Kaunas) 2011, 47, 413–420. [CrossRef] [PubMed]
25. Li, Y.; Zhang, D.; Xu, J.; Shi, J.; Jiang, L.; Yao, N.; Ye, W. Discovery and development of natural heat shock
protein 90 inhibitors in cancer treatment. Acta Pharm. Sin. B 2012, 2, 238–245. [CrossRef]
26. Roe, S.; Prodromou, C.; O’Brien, R.; Ladbury, J.; Piper, P.; Pearl, L. Structural basis for inhibition of the
Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42,
260–266. [CrossRef] [PubMed]
27. Sausville, E.; Tomaszewski, J.; Ivy, P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin.
Curr. Cancer Drug Targets 2003, 3, 377–383. [CrossRef]
28. Schulte, T.; Akinaga, S.; Soga, S.; Sullivan, W.; Stensqard, B.; Toft, D.; Neckers, L. Antibiotic radicicol
binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.
Cell Stress Chaperone 1998, 3, 100–108. [CrossRef]
29. Eccles, S.; Massey, A.; Raynaud, F.; Sharp, S.; Box, G.; Valenti, V. NVP-AUY922: A novel heat shock protein
90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008, 68,
2850–2859. [CrossRef] [PubMed]
30. Canonici, A.; Qadir, Z.; Conlon, N.; Collins, D.; O’Brien, N. The HSP90 inhibitor NVP-AUY922 inhibits
growth of HER2 positive and trastuzumab-resistant breast cancer cells. Invest. New Drugs 2018, 36, 581–589.
[CrossRef]
31. Shapiro, G. Hsp90 inhibitors in clinical development: STA-9090 (Ganetespib). Ann. Oncol. 2011, 22, 16–17.
32. Cavenagh, J.; Oakervee, H.; Baetiong-Caguioa, P.; Davies, F.; Gharibo, M. A phase I/II study of KW-2478, an
Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
Br. J. Cancer 2017, 117, 1295–1302. [CrossRef] [PubMed]
33. Yong, K.; Cavet, J.; Johnson, P.; Morgan, G.; Williams, C. Phase I study of KW-2478, a novel Hsp90 inhibitor,
in patients with B-cell malignancies. Br. J. Cancer 2016, 114, 7–13. [CrossRef] [PubMed]
34. Infante, J.; Weiss, G.; Jones, S.; Tibes, R.; Bauer, T. Phase I dose-escalation studies of SNX-5422, an orally
bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours. Euro. J. Cancer 2014
,
50, 2897–2904. [CrossRef] [PubMed]
35. Gopalakrishnan, R.; Matta, H.; Chaudhary, P. A purine scaffold HSP90 inhibitor BIIB021 has selective activity
against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-
κB. Clin. Cancer Res.
2013, 19, 5016–5026. [CrossRef] [PubMed]
36. He, W.; Hu, H. BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies.
Oncol. Rep. 2018, 40, 3–15. [CrossRef] [PubMed]
37. Canella, A.; Welker, A.; Yoo, J.; Xu, J.; Abas, F. Efficacy of onalespib, a long-acting second-generation HSP90
inhibitor, as a single agent and in combination with temozolomide against malignant gliomas. Clin. Cancer Res.
2017, 23, 6215–6226. [CrossRef] [PubMed]
Sample Availability: Samples of the compounds 4c–4r, 6a–6d, 7a, 7b and 8a are available from the authors.
©
2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).